{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T12:41:16Z","timestamp":1773751276089,"version":"3.50.1"},"reference-count":47,"publisher":"Walter de Gruyter GmbH","issue":"2","license":[{"start":{"date-parts":[[2019,2,20]],"date-time":"2019-02-20T00:00:00Z","timestamp":1550620800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Parasit."],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.2478\/s11686-019-00030-2","type":"journal-article","created":{"date-parts":[[2019,2,20]],"date-time":"2019-02-20T02:05:34Z","timestamp":1550628334000},"page":"236-245","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A Survey on the Adjuvant Role of Naloxone Alone or Combined with Alum in Vaccination Against Fasciolosis in BALB\/c Mice"],"prefix":"10.2478","volume":"64","author":[{"given":"Hakim","family":"Azizi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hadi","family":"Mirzaeei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amin","family":"Bagheri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Bazi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Khamesipour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hajar","family":"Yaghoobi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aliyar","family":"Mirzapour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehrdad","family":"Khatami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samira","family":"Elikaee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2019,2,20]]},"reference":[{"key":"30_CR1","doi-asserted-by":"crossref","unstructured":"Allen, J. E. & Maizels, R. M. (2011). Diversity and dialogue in immunity to helminths. Nature Reviews Immunology, 11, 375\u2013388.","DOI":"10.1038\/nri2992"},{"key":"30_CR2","doi-asserted-by":"publisher","unstructured":"Alter, G. & Sekaly, R. P. (2015). Beyond adjuvants: Antagonizing inflammation to enhance vaccine immunity. Vaccine, 33 Suppl 2, B55-9. \n                    https:\/\/doi.org\/10.1016\/j.vaccine.2015.03.058\n                    \n                  .","DOI":"10.1016\/j.vaccine.2015.03.058"},{"key":"30_CR3","unstructured":"Azizi, H., Kazemi, B., Bandehpour, M., Mohebali, M., Khamesipour, A., Aryaeipour, M., Yaghoobi, H. & Rokni, M. B. (2016). Modulation of the Immune Response to DNA Vaccine Encoding Gene of 8-kDa Subunit of Echinococcus granulosus Antigen B Using Murine Interleukin-12 Plasmid in BALB\/c Mice. Iranian Journal of Parasitology, 11, 480\u2013488."},{"key":"30_CR4","doi-asserted-by":"crossref","unstructured":"Azizi, H., Mirzaeei, H., Nasiri, A. A., Bazi, A., Mirzapour, A., Khatami, M., Nahavandi, K. H., Azimi, A. & Yaghoobi, H. (2018). Naltrexone; as an efficient adjuvant in induction of Th1 immunity and protection against Fasciola hepatica infection. Exp. Parasitol.","DOI":"10.1016\/j.exppara.2018.04.015"},{"key":"30_CR5","doi-asserted-by":"crossref","unstructured":"Burris, S., Norland, J. & Edlin, B. R. (2001). Legal aspects of providing naloxone to heroin users in the United States. International Journal of Drug Policy, 12, 237\u2013248.","DOI":"10.1016\/S0955-3959(01)00080-9"},{"key":"30_CR6","doi-asserted-by":"crossref","unstructured":"Carnevale, S., Pantano, M. L., Kamenetzky, L., Malandrini, J. B., Soria, C. C. & Vel\u00e1squez, J. N. (2015). Molecular diagnosis of natural fasciolosis by DNA detection in sheep faeces. Acta parasitologica, 60, 211\u2013217.","DOI":"10.1515\/ap-2015-0030"},{"key":"30_CR7","doi-asserted-by":"crossref","unstructured":"Cervi, L., Borgonovo, J., Egea, M., Chiapello, L. & Masih, D. (2004). Immunization of rats against Fasciola hepatica using crude antigens conjugated with Freund\u2019s adjuvant or oligodeoxynucleotides. Vet. Immunol. Immunopathol., 97, 97\u2013104.","DOI":"10.1016\/j.vetimm.2003.08.015"},{"key":"30_CR8","doi-asserted-by":"crossref","unstructured":"Changklungmoa, N., Phoinok, N., Yencham, C., Sobhon, P. & Kueakhai, P. (2016). Vaccine potential of recombinant cathepsinL1G against Fasciola gigantica in mice. Vet. Parasitol., 226, 124\u2013131.","DOI":"10.1016\/j.vetpar.2016.07.009"},{"key":"30_CR9","doi-asserted-by":"crossref","unstructured":"Claassen, E., De Leeuw, W., De Greeve, P., Hendriksen, C. & Boersma, W. (1992). Freund\u2019s complete adjuvant: an effective but disagreeable formula. Res. Immunol., 143, 478\u2013483.","DOI":"10.1016\/0923-2494(92)80057-R"},{"key":"30_CR10","doi-asserted-by":"publisher","unstructured":"Dalton, J. P., Robinson, M. W., Mulcahy, G., O\u2019Neill, S. M. & Donnelly, S. (2013). Immunomodulatory molecules of Fasciola hepatica: candidates for both vaccine and immunotherapeutic development. Vet. Parasitol., 195, 272-85. \n                    https:\/\/doi.org\/10.1016\/j.vetpar.2013.04.008\n                    \n                  .","DOI":"10.1016\/j.vetpar.2013.04.008"},{"key":"30_CR11","doi-asserted-by":"crossref","unstructured":"De Gregorio, E., Tritto, E. & Rappuoli, R. (2008). Alum adjuvanticity: unraveling a century old mystery. Eur. J. Immunol., 38, 2068\u20132071.","DOI":"10.1002\/eji.200838648"},{"key":"30_CR12","doi-asserted-by":"publisher","unstructured":"Dixit, A. K., Dixit, P. & Sharma, R. L. (2008). Immunodiagnostic\/protective role of cathepsin L cysteine proteinases secreted by Fasciola species. Vet. Parasitol., 154, 177\u201384. \n                    https:\/\/doi.org\/10.1016\/j.vetpar.2008.03.017\n                    \n                  .","DOI":"10.1016\/j.vetpar.2008.03.017"},{"key":"30_CR13","doi-asserted-by":"crossref","unstructured":"Donnelly, S., Stack, C. M., O\u2019Neill, S. M., Sayed, A. A., Williams, D. L. & Dalton, J. P. (2008). Helminth 2-Cys peroxiredoxin drives Th2 responses through a mechanism involving alternatively activated macrophages. The FASEB Journal, 22, 4022\u20134032.","DOI":"10.1096\/fj.08-106278"},{"key":"30_CR14","unstructured":"Eman, E.-A., Rabia, I., Nagy, F., Zoheiry, M., Diab, T. & Zada, S. (2012). Protective role of purified cysteine proteinases against Fasciola gigantica infection in experimental animals. The Korean journal of parasitology, 50, 45."},{"key":"30_CR15","doi-asserted-by":"crossref","unstructured":"Falc\u00f3n, C., Carranza, F., Mart\u00ednez, F. F., Knubel, C. P., Masih, D. T., Motr\u00e1n, C. C. & Cervi, L. (2010). Excretory-secretory products (ESP) from Fasciola hepatica induce tolerogenic properties in myeloid dendritic cells. Vet. Immunol. Immunopathol., 137, 36\u201346.","DOI":"10.1016\/j.vetimm.2010.04.007"},{"key":"30_CR16","doi-asserted-by":"crossref","unstructured":"Flynn, R. J. & Mulcahy, G. (2008). The roles of IL-10 and TGF-\u03b2 in controlling IL-4 and IFN-\u03b3 production during experimental Fasciola hepatica infection. Int. J. Parasitol., 38, 1673\u20131680.","DOI":"10.1016\/j.ijpara.2008.05.008"},{"key":"30_CR17","doi-asserted-by":"publisher","unstructured":"Flynn, R. J., Mulcahy, G. & Elsheikha, H. M. (2010a). Coordinating innate and adaptive immunity in Fasciola hepatica infection: implications for control. Vet. Parasitol., 169, 235\u201340. \n                    https:\/\/doi.org\/10.1016\/j.vetpar.20https:\/\/doi.org\/10.02.015\n                    \n                  .","DOI":"10.1016\/j.vetpar.20https:\/\/doi.org\/10.02.015"},{"key":"30_CR18","doi-asserted-by":"crossref","unstructured":"Flynn, R. J., Mulcahy, G. & Elsheikha, H. M. (2010b). Coordinating innate and adaptive immunity in Fasciola hepatica infection: implications for control. Veterinary parasitology, 169, 235\u2013240.","DOI":"10.1016\/j.vetpar.2010.02.015"},{"key":"30_CR19","doi-asserted-by":"crossref","unstructured":"Friedman, H., Newton, C. & Klein, T. W. (2003). Microbial infections, immunomodulation, and drugs of abuse. Clin. Microbiol. Rev., 16, 209\u2013219.","DOI":"10.1128\/CMR.16.2.209-219.2003"},{"key":"30_CR20","doi-asserted-by":"crossref","unstructured":"Hillyer, G. V. (2005). Fasciola antigens as vaccines against fascioliasis and schistosomiasis. J. Helminthol., 79, 241\u20137.","DOI":"10.1079\/JOH2005304"},{"key":"30_CR21","doi-asserted-by":"publisher","unstructured":"Jamali, A., Mahdavi, M., Hassan, Z. M., Sabahi, F., Farsani, M. J., Bamdad, T., Soleimanjahi, H., Motazakker, M. & Shahabi, S. (2009). A novel adjuvant, the general opioid antagonist naloxone, elicits a robust cellular immune response for a DNA vaccine. Int. Immunol., 21, 217\u201325. \n                    https:\/\/doi.org\/10.1093\/intimm\/dxn139\n                    \n                  .","DOI":"10.1093\/intimm\/dxn139"},{"key":"30_CR22","doi-asserted-by":"publisher","unstructured":"Jamali, A., Mahdavi, M., Shahabi, S., Hassan, Z. M., Sabahi, F., Javan, M., Farsani, M. J., Parsania, M. & Bamdad, T. (2007). Naloxone, an opioid receptor antagonist, enhances induction of protective immunity against HSV-1 infection in BALB\/c mice. Microb. Pathog., 43, 217\u201323. \n                    https:\/\/doi.org\/10.1016\/j.micpath.2007.06.001\n                    \n                  .","DOI":"10.1016\/j.micpath.2007.06.001"},{"key":"30_CR23","doi-asserted-by":"crossref","unstructured":"Jaros, S., Jaros, D., Wesolowska, A., Zygner, W. & Wedrychowicz, H. (2010). Blocking Fasciola hepatica\u2019s energy metabolism\u2013a pilot study of vaccine potential of a novel gene\u2013phosphoglycerate kinase. Vet. Parasitol., 172, 229\u2013237.","DOI":"10.1016\/j.vetpar.2010.05.008"},{"key":"30_CR24","doi-asserted-by":"crossref","unstructured":"Jayaraj, R., Piedrafita, D., Dynon, K., Grams, R., Spithill, T. W. & Smooker, P. M. (2009). Vaccination against fasciolosis by a multivalent vaccine of stage-specific antigens. Vet. Parasitol., 160, 230\u2013236.","DOI":"10.1016\/j.vetpar.2008.10.099"},{"key":"30_CR25","doi-asserted-by":"crossref","unstructured":"Jayaraj, R., Piedrafita, D., Spithill, T. & Smooker, P. (2012). Evaluation of the immune responses induced by four targeted DNA vaccines encoding the juvenile liver fluke antigen, cathepsin B in a mouse model. Genet. Vaccines Ther., 10, 7.","DOI":"10.1186\/1479-0556-10-7"},{"key":"30_CR26","doi-asserted-by":"publisher","unstructured":"Jazani, N. H., Karimzad, M., Mazloomi, E., Sohrabpour, M., Hassan, Z. M., Ghasemnejad, H., Roshan-Milani, S. & Shahabi, S. (2010). Evaluation of the adjuvant activity of naloxone, an opioid receptor antagonist, in combination with heat-killed Listeria monocytogenes vaccine. Microbes Infect, 12, 382\u20138. \n                    https:\/\/doi.org\/10.1016\/j.micinf.20https:\/\/doi.org\/10.02.001\n                    \n                  .","DOI":"10.1016\/j.micinf.20https:\/\/doi.org\/10.02.001"},{"key":"30_CR27","doi-asserted-by":"publisher","unstructured":"Jazani, N. H., Parsania, S., Sohrabpour, M., Mazloomi, E., Karimzad, M. & Shahabi, S. (2011a). Naloxone and alum synergistically augment adjuvant activities of each other in a mouse vaccine model of Salmonella typhimurium infection. Immunobiology, 216, 744\u201351. \n                    https:\/\/doi.org\/10.1016\/j.imbio.20https:\/\/doi.org\/10.https:\/\/doi.org\/10.005\n                    \n                  .","DOI":"10.1016\/j.imbio.20https:\/\/doi.org\/10.https:\/\/doi.org\/10.005"},{"key":"30_CR28","doi-asserted-by":"publisher","unstructured":"Jazani, N. H., Sohrabpour, M., Mazloomi, E. & Shahabi, S. (2011b). A novel adjuvant, a mixture of alum and the general opioid antagonist naloxone, elicits both humoral and cellular immune responses for heat-killed Salmonella typhimurium vaccine. FEMS Immunol. Med. Microbiol., 61, 54\u201362. \n                    https:\/\/doi.org\/10.1111\/j.1574-695x.20https:\/\/doi.org\/10.00747.x\n                    \n                  .","DOI":"10.1111\/j.1574-695x.20https:\/\/doi.org\/10.00747.x"},{"key":"30_CR29","doi-asserted-by":"publisher","unstructured":"Kelley, J. M., Elliott, T. P., Beddoe, T., Anderson, G., Skuce, P. & Spithill, T. W. (2016). Current Threat of Triclabendazole Resistance in Fasciola hepatica. Trends Parasitol, 32, 458\u201369. \n                    https:\/\/doi.org\/10.1016\/j.pt.2016.03.002\n                    \n                  .","DOI":"10.1016\/j.pt.2016.03.002"},{"key":"30_CR30","doi-asserted-by":"publisher","unstructured":"Khorshidvand, Z., Shahabi, S., Mohamadzade, H., Daryani, A. & Hazrati Tappeh, K. (2016). Mixture of Alum\u2013Naloxone and Alum\u2013Naltrexone as a novel adjuvant elicits immune responses for Toxoplasma gondii lysate antigen in BALB\/c mice. Exp. Parasitol., 162, 28\u201334. \n                    https:\/\/doi.org\/10.1016\/j.exppara.2016.01.001\n                    \n                  .","DOI":"10.1016\/j.exppara.2016.01.001"},{"key":"30_CR31","doi-asserted-by":"crossref","unstructured":"Kueakhai, P., Changklungmoa, N., Riengrojpitak, S., Chaichanasak, P., Meemon, K., Chaithirayanon, K., Chantree, P., Sansri, V., Itagaki, T. & Sobhon, P. (2013). Vaccine potential of recombinant saposin-like protein 2 against Fasciolosis gigantica in mice. Vaccine, 31, 5518\u20135523.","DOI":"10.1016\/j.vaccine.2013.09.027"},{"key":"30_CR32","doi-asserted-by":"crossref","unstructured":"Kueakhai, P., Changklungmoa, N., Waseewiwat, P., Thanasinpaiboon, T., Cheukamud, W., Chaichanasak, P. & Sobhon, P. (2017). Characterization and vaccine potential of Fasciola gigantica saposin-like protein 1 (SAP-1). Vet. Parasitol., 233, 115\u2013122.","DOI":"10.1016\/j.vetpar.2016.12.009"},{"key":"30_CR33","doi-asserted-by":"crossref","unstructured":"McSorley, H. J., Hewitson, J. P. & Maizels, R. M. (2013). Immunomodulation by helminth parasites: defining mechanisms and mediators. Int. J. Parasitol., 43, 301\u2013310.","DOI":"10.1016\/j.ijpara.2012.11.011"},{"key":"30_CR34","doi-asserted-by":"publisher","unstructured":"Meemon, K. & Sobhon, P. (2015). Juvenile-specific cathepsin proteases in Fasciola spp.: their characteristics and vaccine efficacies. Parasitol. Res., 114, 2807\u201313. \n                    https:\/\/doi.org\/10.1007\/s00436-015-4589-6\n                    \n                  .","DOI":"10.1007\/s00436-015-4589-6"},{"key":"30_CR35","doi-asserted-by":"publisher","unstructured":"Molla Hassan, A. T., Hassan, Z. M., Moazzeni, S. M., Mostafaie, A., Shahabi, S., Ebtekar, M. & Hashemi, S. M. (2009). Naloxone can improve the anti-tumor immunity by reducing the CD4\u2009+\u2009CD25\u2009+\u2009Foxp3\u2009+\u2009regulatory T cells in BALB\/c mice. Int. Immunopharmacol., 9, 1381\u20136. \n                    https:\/\/doi.org\/10.1016\/j.intimp.2009.08.008\n                    \n                  .","DOI":"10.1016\/j.intimp.2009.08.008"},{"key":"30_CR36","doi-asserted-by":"publisher","unstructured":"Motaharinia, Y., Rezaee, M. A., Rashidi, A., Jalili, A., Rezaie, M. J., Shapouri, R., Hossieni, W. & Rahmani, M. R. (2013). Induction of protective immunity against brucellosis in mice by vaccination with a combination of naloxone, alum, and heat-killed Brucella melitensis 16\u00a0M. J. Microbiol. Immunol. Infect., 46, 253\u20138. \n                    https:\/\/doi.org\/10.1016\/j.jmii.2012.03.011\n                    \n                  .","DOI":"10.1016\/j.jmii.2012.03.011"},{"key":"30_CR37","doi-asserted-by":"crossref","unstructured":"Pomorska, D. K., Gach, K. & Janecka, A. (2014). Immunomodulatory effects of endogenous and synthetic peptides activating opioid receptors. Mini Rev. Med. Chem., 14, 1148\u201355.","DOI":"10.2174\/1389557515666150101095237"},{"key":"30_CR38","doi-asserted-by":"publisher","unstructured":"Robinson, M. W., Dalton, J. P., O\u2019Brien, B. A. & Donnelly, S. (2013). Fasciola hepatica: the therapeutic potential of a worm secretome. Int. J. Parasitol., 43, 283\u201391. \n                    https:\/\/doi.org\/10.1016\/j.ijpara.2012.11.004\n                    \n                  .","DOI":"10.1016\/j.ijpara.2012.11.004"},{"key":"30_CR39","doi-asserted-by":"publisher","unstructured":"Sansri, V., Meemon, K., Changklungmoa, N., Kueakhai, P., Chantree, P., Chaichanasak, P., Lorsuwannarat, N., Itagaki, T. & Sobhon, P. (2015). Protection against Fasciola gigantica infection in mice by vaccination with recombinant juvenile-specific cathepsin L. Vaccine, 33, 1596\u2013601. \n                    https:\/\/doi.org\/10.1016\/j.vaccine.2015.02.010\n                    \n                  .","DOI":"10.1016\/j.vaccine.2015.02.010"},{"key":"30_CR40","doi-asserted-by":"crossref","unstructured":"Serradell, M. C., Guasconi, L., Cervi, L., Chiapello, L. S. & Masih, D. T. (2007). Excretory-secretory products from Fasciola hepatica induce eosinophil apoptosis by a caspase-dependent mechanism. Vet. Immunol. Immunopathol., 117, 197\u2013208.","DOI":"10.1016\/j.vetimm.2007.03.007"},{"key":"30_CR41","doi-asserted-by":"crossref","unstructured":"Shahabi, S., Azizi, H., Mazloomi, E., Tappeh, K. H., Seyedi, S. & Mohammadzadeh, H. (2014). A novel adjuvant, the mixture of alum and naltrexone, augments vaccine-induced immunity against Plasmodium berghei. Immunol. Invest., 43, 653\u2013666.","DOI":"10.3109\/08820139.2014.914531"},{"key":"30_CR42","doi-asserted-by":"publisher","unstructured":"Velashjerdi Farahani, S., Reza Aghasadeghi, M., Memarnejadian, A., Faezi, S., Shahosseini, Z. & Mahdavi, M. (2016). Naloxone\/alum mixture a potent adjuvant for HIV-1 vaccine: induction of cellular and poly-isotypic humoral immune responses. Pathog Glob Health, 110, 39\u201347. \n                    https:\/\/doi.org\/10.1179\/2047773215y.0000000035\n                    \n                  .","DOI":"10.1179\/2047773215y.0000000035"},{"key":"30_CR43","doi-asserted-by":"publisher","unstructured":"Vicente, B., Lopez-Aban, J., Rojas-Caraballo, J., del Olmo, E., Fernandez-Soto, P. & Muro, A. (2016). Protection against Schistosoma mansoni infection using a Fasciola hepatica-derived fatty acid binding protein from different delivery systems. Parasit Vectors, 9, 216. \n                    https:\/\/doi.org\/10.1186\/s13071-016-1500-y\n                    \n                  .","DOI":"10.1186\/s13071-016-1500-y"},{"key":"30_CR44","doi-asserted-by":"publisher","unstructured":"Vicente, B., Lopez-Aban, J., Rojas-Caraballo, J., Perez del Villar, L., Hillyer, G. V., Martinez-Fernandez, A. R. & Muro, A. (2014). A Fasciola hepatica-derived fatty acid binding protein induces protection against schistosomiasis caused by Schistosoma bovis using the adjuvant adaptation (ADAD) vaccination system. Exp. Parasitol., 145, 145\u201351. \n                    https:\/\/doi.org\/10.1016\/j.exppara.2014.08.007\n                    \n                  .","DOI":"10.1016\/j.exppara.2014.08.007"},{"key":"30_CR45","doi-asserted-by":"publisher","unstructured":"Wesolowska, A., Jaros, S., Norbury, L. J., Jaros, D., Zygner, W. & Wedrychowicz, H. (2013). Microarray analysis of rat immune responses to liver fluke infection following vaccination with Fasciola hepatica phosphoglycerate kinase. Exp. Parasitol., 134, 33\u20138. \n                    https:\/\/doi.org\/10.1016\/j.exppara.2013.01.013\n                    \n                  .","DOI":"10.1016\/j.exppara.2013.01.013"},{"key":"30_CR46","doi-asserted-by":"crossref","unstructured":"Wilson\u2010Welder, J. H., Torres, M. P., Kipper, M. J., Mallapragada, S. K., Wannemuehler, M. J. & Narasimhan, B. (2009). Vaccine adjuvants: current challenges and future approaches. J. Pharm. Sci., 98, 1278\u20131316.","DOI":"10.1002\/jps.21523"},{"key":"30_CR47","unstructured":"Yasaghi, M. & Mahdavi, M. (2016). Potentiation of human papilloma vaccine candidate using naloxone\/alum mixture as an adjuvant: increasing immunogenicity of HPV-16E7d vaccine. Iran J Basic Med Sci, 19, 1003\u20131009."}],"container-title":["Acta Parasitologica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.2478\/s11686-019-00030-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.2478\/s11686-019-00030-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.2478\/s11686-019-00030-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,19]],"date-time":"2020-02-19T19:04:56Z","timestamp":1582139096000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.2478\/s11686-019-00030-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,20]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["30"],"URL":"https:\/\/doi.org\/10.2478\/s11686-019-00030-2","relation":{},"ISSN":["1230-2821","1896-1851"],"issn-type":[{"value":"1230-2821","type":"print"},{"value":"1896-1851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,20]]},"assertion":[{"value":"13 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All experiments were performed according to the Animal Care and Use Protocol of Zabol University of Medical Sciences. The study was approved by Ethical Committee of Zabol University of Medical Sciences.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}